Ionis Pharmaceuticals Inc. (NASDAQ:IONS)‘s stock had its “sell” rating reaffirmed by investment analysts at Jefferies Group in a report released on Thursday. They currently have a $17.00 target price on the stock. Jefferies Group’s price target would suggest a potential downside of 55.71% from the company’s previous close.

The analysts wrote, “Ionis Pharmaceuticals Inc Receives a Sell from Jefferies | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=07a193bd66&wpp_id=459571’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Ionis Pharmaceuticals Inc Receives a Sell from Jefferies”

Several other analysts have also commented on IONS. Cowen and Company reissued a “hold” rating on shares of Ionis Pharmaceuticals in a report on Thursday, July 14th. Needham & Company LLC reissued a “buy” rating and issued a $55.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, July 14th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $35.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, July 15th. Leerink Swann reissued a “market perform” rating and issued a $26.00 price objective (down from $39.00) on shares of Ionis Pharmaceuticals in a report on Monday, July 18th. Finally, BMO Capital Markets raised their price objective on Ionis Pharmaceuticals from $25.00 to $40.00 and gave the company a “market perform” rating in a report on Monday, August 1st. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $40.61.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) opened at 38.38 on Thursday. The stock’s market cap is $4.64 billion. The company’s 50-day moving average price is $31.41 and its 200 day moving average price is $30.23. Ionis Pharmaceuticals has a 12-month low of $19.59 and a 12-month high of $63.71.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company had revenue of $110.90 million for the quarter, compared to analysts’ expectations of $114.65 million. Ionis Pharmaceuticals had a negative net margin of 128.94% and a negative return on equity of 126.88%. The company’s quarterly revenue was up 125.9% compared to the same quarter last year. On average, equities analysts predict that Ionis Pharmaceuticals will post ($1.11) earnings per share for the current year.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 5,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, November 7th. The stock was sold at an average price of $34.00, for a total value of $170,000.00. Following the sale, the senior vice president now owns 15,803 shares in the company, valued at $537,302. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 11,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $36.61, for a total value of $402,710.00. Following the completion of the sale, the chairman now owns 35,029 shares in the company, valued at approximately $1,282,411.69. The disclosure for this sale can be found here. 1.86% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of IONS. Rockefeller Financial Services Inc. acquired a new stake in Ionis Pharmaceuticals during the second quarter worth approximately $114,000. US Bancorp DE increased its stake in Ionis Pharmaceuticals by 37.8% in the second quarter. US Bancorp DE now owns 5,952 shares of the company’s stock worth $139,000 after buying an additional 1,634 shares in the last quarter. GAM Holding AG increased its stake in Ionis Pharmaceuticals by 118.5% in the second quarter. GAM Holding AG now owns 7,727 shares of the company’s stock worth $180,000 after buying an additional 4,191 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Ionis Pharmaceuticals by 31.1% in the second quarter. Teacher Retirement System of Texas now owns 8,577 shares of the company’s stock worth $200,000 after buying an additional 2,036 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Ionis Pharmaceuticals by 1.6% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 8,966 shares of the company’s stock worth $209,000 after buying an additional 140 shares in the last quarter. Institutional investors own 89.56% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.

5 Day Chart for NASDAQ:IONS

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.